» Articles » PMID: 12917689

CYLD is a Deubiquitinating Enzyme That Negatively Regulates NF-kappaB Activation by TNFR Family Members

Overview
Journal Nature
Specialty Science
Date 2003 Aug 15
PMID 12917689
Citations 427
Authors
Affiliations
Soon will be listed here.
Abstract

Familial cylindromatosis is an autosomal dominant predisposition to tumours of skin appendages called cylindromas. Familial cylindromatosis is caused by mutations in a gene encoding the CYLD protein of previously unknown function. Here we show that CYLD is a deubiquitinating enzyme that negatively regulates activation of the transcription factor NF-kappaB by specific tumour-necrosis factor receptors (TNFRs). Loss of the deubiquitinating activity of CYLD correlates with tumorigenesis. CYLD inhibits activation of NF-kappaB by the TNFR family members CD40, XEDAR and EDAR in a manner that depends on the deubiquitinating activity of CYLD. Downregulation of CYLD by RNA-mediated interference augments both basal and CD40-mediated activation of NF-kappaB. The inhibition of NF-kappaB activation by CYLD is mediated, at least in part, by the deubiquitination and inactivation of TNFR-associated factor 2 (TRAF2) and, to a lesser extent, TRAF6. These results indicate that CYLD is a negative regulator of the cytokine-mediated activation of NF-kappaB that is required for appropriate cellular homeostasis of skin appendages.

Citing Articles

The Role of Ubiquitin-Proteasome System (UPS) in Asthma Pathology.

Deng S, Ding L, Qian Y, Huang X J Asthma Allergy. 2025; 18:307-330.

PMID: 40046173 PMC: 11881607. DOI: 10.2147/JAA.S490039.


FABP5 is a key player in metabolic modulation and NF-κB dependent inflammation driving pleural mesothelioma.

Vecchio E, Gallo R, Mimmi S, Gentile D, Giordano C, Straface E Commun Biol. 2025; 8(1):324.

PMID: 40016284 PMC: 11868402. DOI: 10.1038/s42003-025-07754-0.


Suppression of CYLD by HER3 confers ovarian cancer platinum resistance via inhibiting apoptosis and by inducing drug efflux.

Zhang Y, Qiu J, Wang W, Sun F, Wang X, Liu W Exp Hematol Oncol. 2025; 14(1):21.

PMID: 40012003 PMC: 11866804. DOI: 10.1186/s40164-025-00620-z.


RIPK1 in necroptosis and recent progress in related pharmaceutics.

Yao K, Shi Z, Zhao F, Tan C, Zhang Y, Fan H Front Immunol. 2025; 16:1480027.

PMID: 40007541 PMC: 11850271. DOI: 10.3389/fimmu.2025.1480027.


Ablation of the deubiquitinating enzyme cylindromatosis (CYLD) augments STAT1-mediated M1 macrophage polarization and fosters control.

Schmidt C, Harit K, Traidl S, Naumann M, Werfel T, Roesner L Front Immunol. 2025; 16:1507989.

PMID: 39958342 PMC: 11827430. DOI: 10.3389/fimmu.2025.1507989.